UAE – Abu Dhabi’s Burjeel Medical City (BMC) and Digipharm, an innovative healthcare solutions provider based in the United Kingdom, have teamed up to co-design, and validate a new patient care model in the United Arab Emirates.
Burjeel Medical City, the flagship facility of Burjeel Holdings, is one of eight facilities licensed to perform organ and tissue transplants in the UAE.
As part of the new deal, BMC and Digipharm will work closely together to implement digitally enabled Value-based Healthcare (VBHC) and Value-based Procurement (VBP) provisions.
BMC will work with Digipharm to lay the foundations to implement Digipharm’s Reimburse Platform and the Digihealth (patient-reported outcomes) Application to enable VBHC and VBP at the hospital.
The agreement was signed by Mr. John Sunil, Chief Executive Officer of Burjeel Holdings, and Ahmed Abdulla, CEO of Digipharm.
Expressing his thoughts on this strategic alliance, Ahmed Abdulla, CEO of Digipharm, said: “We are proud to collaborate with one of the UAE’s largest private healthcare providers. Our platform will optimize the patient journey by identifying gaps and potential risks to deliver better outcomes.”
Burjeel Medical City and Digipharm have also agreed to explore new opportunities for real-time application of pre-agreed, personalized contract stipulations after validation of the new model for patient care in the UAE.
The partnership between BMC, the flagship facility of Burjeel Holdings, and Digipharm targets patients and their families across the UAE.
It could pave the way to similar impactful collaborations that can bolster the UAE’s transformation journey into a global leader in the healthcare space.
“This collaboration will allow us, as a solution provider, to validate our delivery models in host institutions and patient populations outside of the UK and Europe in a country that is leading digital transformation in the region,” asserted Mr. Abdulla
Under the new deal, Burjeel Medical City and Digipharm will leverage their respective strengths and expertise to provide newer health technologies and create an enhanced end-to-end patient experience in the UAE.
The multi-phase partnership will initially develop a framework to measure value by understanding the patient’s journey when the patient first steps into the hospital until the required treatment is provided.
Commenting on the significance of this new deal, Mr. John Sunil, CEO of Burjeel Holdings said: “At Burjeel Holdings, we firmly believe that technology is a game-changer for advancing healthcare delivery. By leveraging cutting-edge technology, we aim to enhance the patient experience, improve outcomes and drive innovation in healthcare.”
Value-creation and the elimination of waste or poor outcomes lie at the heart of this multi-phase partnership involving Burjeel Medical City and Digipharm.
In the pilot phase, the new patient care model will be designed around the Bone Marrow Transplantation program adopted at Burjeel Medical City.
BMC’s Bone Marrow Transplantation Program has completed 78 transplant procedures, including 30 in the pediatric population, since its inception in 2022.
It has performed allogenic and autologous transplants in patients with leukemia, thalassemia, sickle cell disease, primary immunodeficiency, and hemophagocytic lymphohistiocytosis (HLH).
“We are excited to explore how the new technology can be used to improve Bone Marrow Transplant outcomes,” underscored Mr. Sunil.
Ultimately, BMC and Digipharm have joined forces to empower patients with new innovative health technologies that ensure optimized clinical pathways, and improved patient outcomes and experiences.
The Digipharm’s Reimburse Platform and the Digihealth (patient-reported outcomes) Application will be deployed to other medical specialties and subspecialties offered at Burjeel Medical City following the success of the initiation phase.
Additionally, the new system will help BMC healthcare professionals in identifying the pain points a patient faces during the journey and estimate the associated cost at each step.
Accurate patient diagnosis helps to design solutions around the care provided for the best outcomes and identify opportunities to reduce the cost of care provision.
Moreover, Digipharm’s Reimburse Platform will allow BMC to gather remote patient experience feedback and reporting, alongside facilitating patient-reported outcome measurement collection through a dedicated application.
The Digihealth application hosts International Consortium for Health Outcomes Measurements (ICHOM) Standard Sets and various established questionnaires that are widely used to inform healthcare commissioning and health technology assessments.
Unsurprisingly, the implementation of digitally enabled VBHC and VBP provisions at Burjeel Medical City has the potential to revolutionize the digital healthcare ecosystem in the UAE.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
